Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Thromboembolism × Plasma cell × Clear all
NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Celgene

Completed
1,149 enrolled
GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT03099031 2019-12-16

PREDICARE

LEO Pharma

Completed
420 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Digestive System Neoplasms, Intestinal Neoplasms, Leukemia, Lung Neoplasms, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Prostatic Neoplasms, Thromboembolism, Urogenital Neoplasms, Vascular Diseases, Colorectal Neoplasms, Hemostatic Disorders, Venous Thrombosis, Venous Thromboembolism